After two thousand years of operation, the Catholic church has grown more risk-averse than during its start-up days. But that has not stopped the Vatican from buying a lossmaking Pfizer spin-off focused on risky early-stage cancer research.
Nerviano Medical Systems, based outside Milan, is now one of Europe's largest oncological research centres, dedicated to developing anti-tumour drugs using the so-called targeted approach that addresses specific molecular processes in cancer cell growth, leaving healthy cells intact.
Source: FT
No comments:
Post a Comment